REG - Trellus Health PLC - Funding Update

Trellus HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260402:nRSB1469Za&default-theme=true

RNS Number : 1469Z  Trellus Health PLC  02 April 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC
AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE
REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED
KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA") AND AS
MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED
TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK
MAR").

 

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Funding Update

 

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus
Elevate®, a digital platform that integrates data analytics with
personalised, scientifically proven resilience programmes and value-based
solutions to manage complex chronic conditions, announces that it has entered
into an unsecured loan agreement with the Dr. Marla Dubinsky, Chief Executive
Officer and Co-Founder, with a principal amount of US$50,000 (the "Loan
Note").

 

Loan Note Terms

 

The Loan Note will accrue interest at an annual rate of 5%, payable in cash at
maturity of the loan. The loan term is 12 months.

 

Cash Runway

 

The proceeds from the Loan Note will extend the Company's cash runway into
late April 2026. The Convertible Facility provided by Alumni Capital LLC
remains in place, although utilisation continues to be currently constrained
by market conditions.

 

As stated in the announcement of 27 March 2026, the Board remains supportive
of the Company's commercial strategy and is engaged in ongoing discussions
regarding a range of potential funding options to further extend the Company's
cash runway.

 

Related Party Transaction

 

The Loan Note is deemed to be a related party transaction under AIM Rule 13 of
the AIM Rules for Companies as Dr. Marla Dubinsky is a director of the
Company. The Company's Independent Directors consider, having consulted with
the Nominated Adviser, Singer Capital Markets, that the terms of the related
party transaction are fair and reasonable insofar as the shareholders of the
Company are concerned.

 

Enquiries:

 

 Trellus Health plc                                                                      https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder                                     Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)
 Philip Davies / Jalini Kalaravy / Samed Ethemi                Tel: +44 (0)20 7496 3000 303/

 Walbrook PR                   Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                           (mailto:trellus@walbrookpr.com)
 Lianne Applegarth /                                                               Mob: +44 (0)7584 391 303/
 Alice Woodings                                                                                                          +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

 

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSSMFMFEMSELL



            Copyright 2019 Regulatory News Service, all rights reserved